Ferroptosis: A New Culprit in the Failing Heart
A comprehensive review in Cardiovascular Research synthesizes the growing evidence linking ferroptosis—a form of iron-dependent, lipid peroxidation-driven cell death—to the progression of heart failure. The analysis details how this pathway is activated across diverse cardiomyopathy models, from ischemic and pressure-overloaded hearts to those damaged by metabolic disease or toxins like doxorubicin. Crucially, the review highlights that several cardiometabolic drugs with proven clinical efficacy, including SGLT2 inhibitors and sacubitril/valsartan, appear to mitigate ferroptotic activity. Early human data supports this, showing distinct ferroptosis-related molecular signatures in failing heart tissue and altered biomarker profiles in patients on these therapies.
Why it might matter to you: The mechanistic link between metabolic dysregulation, iron homeostasis, and cell death in heart failure has direct parallels to the pathophysiology of metabolic liver diseases like NASH. Understanding how established drugs exert pleiotropic effects by modulating ferroptosis could inform novel therapeutic strategies for hepatic steatosis, fibrosis, and end-stage liver disease. For hepatologists, this research underscores the importance of systemic metabolic crosstalk and may point to repurposing opportunities or biomarker development for conditions like drug-induced liver injury and cirrhosis.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
